Cerbios has been rewarded at Swiss Venture Club Prix 2015 based on its continued Innovation and Sustainability
Cerbios-Pharma SA (from now on “Cerbios”) has been awarded second place at the bi-annual Swiss Venture Club Prix.
“This is an important recognition for Cerbios, the founders that created it in the late 70’s, the management and all employees that made this possible” confirms Gabriel Haering, Cerbios’ CEO.
“Being one of the six finalists chosen among 50 companies representing different industrial branches in Ticino was already a great achievement. Reaching the second place among the six finalist is splendid!”
The main criteria for the choice of finalists and winners were the following:
- Innovation as key company value
- Regional presence and impact at different levels
- An excellent track record
- Leadership in the reference market
- Operational sustainability
This award is not only a recognition for Cerbios’ strategy and approach but also a commitment towards the future in order to maintain the high standard achieved.
For more details about SVC Prix, click here.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.
Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.
Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.